If you have just started semaglutide at 0.25mg or are considering treatment, one of your first questions is probably about timing. When will you start to feel different? When does weight loss begin? And how does this introductory dose fit into the bigger picture?

We put together this evidence-based timeline so you can set realistic expectations. Keep in mind that individual results vary significantly, and your prescribing physician is the best source of guidance for your specific situation.

Understanding the 0.25mg Phase

Before we walk through the timeline, it is important to understand why 0.25mg exists in the treatment protocol. This dose is the introductory titration step. It was not designed to produce maximum weight loss. Its primary job is to help your body adjust to the medication with fewer gastrointestinal side effects.

In the STEP clinical trials, participants spent only four weeks at 0.25mg before escalating to 0.5mg. During this window, the medication begins building to steady-state concentration in your body. Semaglutide has a long half-life of approximately one week, meaning it takes about four to five weeks of consistent dosing to reach a stable level in your bloodstream.

Week-by-Week Results Timeline at 0.25mg

Week 1: The First Injection

During the first week, your body is just beginning to process semaglutide. The drug concentration in your blood is still building. Most patients do not notice dramatic changes during this first week, though some report:

• A subtle decrease in appetite, particularly in the 24 to 48 hours following the injection
• Mild nausea or stomach awareness, usually temporary
• Slightly reduced interest in snacking or large portions

Others feel no difference at all during week one. Both experiences are normal.

Week 2: Early Signals

By the second injection, semaglutide levels in your blood are higher than they were in week one. Some patients begin to notice more consistent appetite changes. You might find that you feel full sooner during meals or that the urge to eat between meals is weaker.

GI side effects, if they are going to appear, often show up during week two. Mild nausea, slight bloating, or changes in bowel habits are the most commonly reported symptoms.

Week 3: Building Momentum

By week three, semaglutide is approaching (but has not yet reached) steady-state levels. Many patients report that appetite suppression becomes more noticeable and consistent. You may find it easier to make healthier food choices simply because the cravings are less intense.

Some patients see a small amount of weight loss by this point, often in the range of one to three pounds. This can come from reduced caloric intake driven by lower appetite. However, some patients see no scale change yet, which is also completely normal at this dose.

Week 4: Approaching Steady State

By the end of week four, you are nearing the steady-state concentration for the 0.25mg dose. Your body has had time to adjust, and most early GI side effects have improved or resolved. Appetite changes, if present, are typically at their most consistent for this dose level.

In the clinical trials, this is the point where researchers escalated participants to 0.5mg. Your physician will evaluate your tolerance and progress to determine whether you are ready to move to the next dose or whether staying at 0.25mg for additional time makes sense.

Clinical Trial Dosing Context

The STEP 1 trial, which studied semaglutide 2.4mg for weight management, showed the following outcomes over the full treatment period:

• Average weight loss of approximately 14.9% of body weight over 68 weeks at the 2.4mg maintenance dose
• Weight loss was progressive throughout the study, with the steepest declines occurring during the mid-dose escalation and early maintenance phases
• At the 0.25mg titration dose specifically, weight loss was minimal compared to the later phases

This data reinforces the point: 0.25mg is a stepping stone. It is part of a larger treatment arc, and the meaningful weight loss results reported in clinical trials came from higher maintenance doses sustained over months.

How Titration Shapes Your Results

Your results timeline extends well beyond the first four weeks. The titration process in clinical trials spanned roughly 16 weeks before participants reached the full maintenance dose. Each step up brings increased GLP-1 receptor activation, stronger appetite suppression, and greater potential for weight loss.

Rushing through titration is not advisable. Patients who escalate too quickly often experience more severe GI side effects, which can lead to poor adherence or the need to step back down. A measured, physician-guided approach tends to produce better long-term outcomes.

What Affects Your Personal Timeline

Several variables can shift your results earlier or later compared to average timelines:

• Starting weight: Patients with higher starting body weight may notice proportionally less effect at the introductory dose.
• Metabolic rate: Individual differences in how quickly you metabolize the drug can influence when you feel its effects.
• Diet quality: Patients who pair semaglutide with balanced nutrition often see better and earlier results than those who make no dietary changes.
• Physical activity: Regular exercise supports the metabolic effects of GLP-1 therapy and can accelerate outcomes.
• Sleep and stress: Poor sleep and chronic stress can blunt weight loss through hormonal pathways that GLP-1 agonists do not directly address.
• Medications: Other prescriptions you take may interact with semaglutide or influence metabolic parameters. Always discuss your full medication profile with your physician.

Safety Notes for the First Month

The 0.25mg dose has a favorable safety profile. The most common side effects during this phase are gastrointestinal: nausea, constipation, diarrhea, and abdominal discomfort. These are generally mild and self-limiting.

Contact your physician immediately if you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, or any symptom that concerns you. While serious events are rare at this dose, prompt communication with your care team is always the right approach.

Setting Realistic Expectations

We find that patients who approach the 0.25mg phase with the right mindset tend to have better long-term outcomes. Here is what we recommend:

• Do not fixate on the scale during month one. The introductory dose is about adjustment, not dramatic results.
• Track non-scale indicators. Appetite changes, portion sizes, energy levels, and cravings are all meaningful signals that the medication is working.
• Stay consistent. Take your injection on the same day each week. Consistency helps maintain steady drug levels.
• Build healthy habits now. The habits you establish during the titration phase will compound as your dose increases.

Frequently Asked Questions

Is it normal to not lose weight on semaglutide 0.25mg?

Yes. The 0.25mg dose is a titration step, not a maintenance dose. Many patients see little to no weight change during the first four weeks. Clinically significant weight loss typically develops at higher doses sustained over several months.

When will I feel less hungry on 0.25mg?

Appetite changes are variable. Some patients notice reduced hunger within the first one to two weeks, while others do not feel a significant difference until the dose increases. Both responses are within the range of normal.

How much weight can I expect to lose overall with semaglutide?

In the STEP 1 trial, participants lost an average of approximately 14.9% of body weight over 68 weeks at the 2.4mg maintenance dose. Individual results vary based on many factors, including adherence, lifestyle, and dosing.

Should I change my diet when starting semaglutide?

We recommend working with your physician or a registered dietitian to optimize your nutrition while on GLP-1 therapy. At minimum, eating smaller meals, prioritizing protein, staying hydrated, and limiting highly processed foods can support your results and reduce GI side effects.

Can I skip the 0.25mg dose and start higher?

The titration phase exists to protect you from more severe side effects. Skipping it is not recommended. Your physician will determine the safest starting point based on your medical history.

Your Timeline Starts With the Right Support

At FormBlends, our physicians build personalized treatment timelines based on your health profile, tolerance, and goals. We monitor your progress throughout the titration process and adjust your plan as needed to optimize both safety and results.

Ready to start your weight loss journey with physician-guided GLP-1 therapy? Schedule your consultation with FormBlends today.